![N-Methyl-N-[(3-methyldithio)-1-oxopropyl]-L-alanine](/upload/banner/navi-3853.jpg)
N-Methyl-N-[(3-methyldithio)-1-oxopropyl]-L-alanine
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
![N-Methyl-N-[(3-methyldithio)-1-oxopropyl]-L-alanine](https://resource.bocsci.com/structure/138148-62-6.gif)
| Category | Mycotoxins |
| Catalog number | BBF-05899 |
| CAS | 138148-62-6 |
| Molecular Weight | 237.34 |
| Molecular Formula | C8H15NO3S2 |
| Purity | ≥95% |
Online Inquiry
Description
N-Methyl-N-[(3-methyldithio)-1-oxopropyl]-L-alanine, a microtubule inhibitor, is a PEG linker used in antibody-drug-conjugation (ADC).
Specification
| Synonyms | (S)-2-(N-Methyl-3-(methyldisulfanyl)propanamido)propanoic acid; L-Alanine, N-methyl-N-[3-(methyldithio)-1-oxopropyl]-; N-Methyl-N-[3-(methyldisulfanyl)propanoyl]-L-alanine |
| IUPAC Name | (2S)-2-[methyl-[3-(methyldisulfanyl)propanoyl]amino]propanoic acid |
| Canonical SMILES | CC(C(=O)O)N(C)C(=O)CCSSC |
| InChI | InChI=1S/C8H15NO3S2/c1-6(8(11)12)9(2)7(10)4-5-14-13-3/h6H,4-5H2,1-3H3,(H,11,12)/t6-/m0/s1 |
| InChI Key | OPKAUPROPWPLTQ-LURJTMIESA-N |
Properties
| Boiling Point | 406.3±30.0°C (Predicted) |
| Melting Point | 103-104°C |
| Density | 1.263±0.06 g/cm3 (Predicted) |
Reference Reading
1. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer
Myra F Barginear, Veena John, Daniel R Budman Mol Med. 2013 Jan 22;18(1):1473-9. doi: 10.2119/molmed.2012.00302.
Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Although trastuzumab is a very active agent in HER2-overexpressing breast cancer, the majority of patients with metastatic HER2-overexpressing breast cancer who initially respond to trastuzumab develop resistance within 1 year of initiation of treatment and, in the adjuvant setting, progress despite trastuzumab-based therapy. The antibody-drug conjugate trastuzumab-DM1 (T-DM1) was designed to combine the biological activity of trastuzumab with the targeted delivery of a highly potent antimicrotubule agent, DM1 (N-methyl-N-[3-mercapto-1-oxopropyl]-l-alanine ester of maytansinol), a maytansine derivative, to HER2-overexpressing breast cancer cells. T-DM1 is the first antibody-drug conjugate with a nonreducible thioether linker in clinical trials. Phase I and II clinical trials of T-DM1 as a single agent and in combination with paclitaxel, docetaxel and pertuzumab have shown clinical activity and a favorable safety profile in patients with HER2-positive metastatic breast cancer. Two randomized phase III trials of T-DM1 are awaiting final results; the EMILIA trial is evaluating T-DM1 compared with lapatinib plus capecitabine, and early positive results have been reported. The MARIANNE trial is evaluating T-DM1 plus placebo versus T-DM1 plus pertuzumab versus trastuzumab plus a taxane. Here, we summarize evidence from clinical studies and discuss the potential clinical implications of T-DM1.
Recommended Products
| BBF-01825 | Loganin | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
